Lung transplantation has evolved into a life-saving treatment with improved quality of life for patients with end-stage respiratory failure unresponsive to other medical or surgical interventions. With improving survival rates, the number of lung transplant recipients with preexisting and posttransplant comorbidities that require attention continues to increase. A partnership between transplant and nontransplant care providers is necessary to deliver comprehensive and optimal care for transplant candidates and recipients. The goals of this partnership include timely referral and assistance with transplant evaluation, optimization of comorbidities and preparation for transplantation, management of common posttransplant medical comorbidities, immunization, screening for malignancy, and counseling for a healthy lifestyle to maximize the likelihood of a good outcome. We aim to provide an outline of the main aspects of the care of candidates for and recipients of lung transplants for nontransplant physicians and other care providers.
With improving survival rates, the number of people living with lung transplants has increased and as of 2014 exceeded 11,000 in the United States, representing the highest number of living lung recipients since the first successful lung transplant. 2 Despite this finding, the LTx procedure rate falls significantly short of the number of patients with respiratory failure in need of lung transplants. Among those patients who make it to the waiting list in the United States, an average of 300 patients die annually while waiting for lung transplants. 4 The ever-increasing number of people in need of lung transplants and the progressive improvement in posttransplant survival suggest that an effective partnership between transplant and nontransplant providers will be required for continued progress in quality of life and outcomes. The long-term care of the transplant recipient is focused on the prevention of complications, recognition of emergent medical issues and optimization of immunosuppression, and return to independent daily living. Primary care physicians (PCPs) are uniquely positioned to assess these patients for emerging issues, manage common comorbidities, counsel for healthy lifestyle, and screen for malignancy ( Table 1) .
Coordination of Care
Although collaboration between specialists and community physicians and care providers leads to improved outcomes 5 and elimination of errors by means of sharing information, there are no established standards for coordination of care before or after receiving lung transplants. Poor communication between providers can impair patient safety, decrease patient satisfaction, and increase the economic burden of health care. The facilities, support staff, and resources at the PCP office make it ideal for delivering preventive care and managing chronic comorbidities effectively.
In lung transplant recipients, the complex interactions of the host, graft, immunosuppressive drugs, and the patient's environment pose challenges. These challenges include nonspecific symptoms and signs of allograft rejection, infection, malignancy, medication toxicities, and drug interactions. The American Society of Transplantation recommends that significant changes in the clinical condition of lung transplant recipients are communicated to the transplant center promptly. 6 Even prior to a patient receiving a lung transplant, changes in functional capacity, worsening oxygenation, hospitalizations, infections, pulmonary embolism, stroke, need for continuous mechanical ventilation, pulmonary hypertension, elevation in serum creatinine levels, or deterioration in arterial blood gasses in lung transplant candidates should all be communicated to the transplant center because they may affect the listing status or transplant candidacy.
Pretransplant Phase
Candidate selection begins with a referral from the nontransplant pulmonologist or PCP. The referring physician often has an established relationship with the patient and can provide historical background data and salient details of adherence and social support. The timing of patient referral is of the utmost importance and permits thorough evaluation, identification and optimization of comorbidities, improvement in 
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Health maintenance (as above) Adherence chestjournal.org nutritional and functional status, and preparation of the patient and family for the life-altering event of LTx. 7 Identification and referral of potential transplant candidates for screening should occur early enough to survive the prolonged waiting list period and not too late to preclude listing. In adults, a lung transplant is indicated in a broad spectrum of end-stage pulmonary diseases (Table 2) . 8, 9 COPD, idiopathic pulmonary fibrosis, and cystic fibrosis (CF) account for most lung transplants performed worldwide. 10 Disease-specific candidate selection for a lung transplant usually follows the updated international guidelines ( Table 2) . [7] [8] [9] Recent malignancy, active hepatitis B virus or hepatitis C virus (HCV) infection, severe psychiatric illness, continued tobacco and other substance use, inability to demonstrate a reliable and active social support structure, and recurrent medical noncompliance with clinical care still constitute absolute contraindications to receiving a lung transplant (Table 3) . If deemed suitable candidates, patients older than 65 years may undergo a lung transplant without any significant increase in short-term mortality, 9 though, as expected, longer-term survival is less than that in younger patients. 11, 12 In contrast to that in uninfected patients, outcomes in lung transplant recipients with chronic (HCV) infections are less well established. Although a previous retrospective single-center study described no difference in survival between lung transplant recipients who were HCV positive and those who were HCV negative, 13 38 Efforts targeted at these comorbidities to optimize the patient and prepare for surgery may reduce the risk of complications and improve outcomes.
Pulmonary Rehabilitation
End-stage pulmonary diseases are frequently associated with sedentariness, deconditioning, and skeletal muscle dysfunction 39 that may be improved by pulmonary rehabilitation. Pulmonary rehabilitation enhances exercise capacity and maintains oxygen uptake in candidates for lung transplant. [40] [41] [42] Identifying and targeting patients who are at risk and frail before lung transplant may reduce perioperative complications and 44 and may have decreased survival after lung transplant. 44, 47 Similarly, data from the United Network for Organ Sharing show that patients who are obese constitute more than 11% of US lung transplant recipients. 48 Given that 69% of US adults are overweight or obese, this percentage is likely to increase.
As observed in candidates for lung transplant with low BMI, being overweight or obese was previously associated with increased mortality risk. 44, 49 However, a large study suggests that survival in the first year after transplant may not be decreased in patients with a BMI 25.0 to 34.9 kg/m 2 . 45 Current guidelines include class II obesity as an absolute and class I obesity as a relative contraindication for lung transplant 7 (Table 3) .
Although leptin levels may supersede BMI as a measure of adiposity and better predict 1-year mortality after lung transplant, BMI remains a readily available tool in guiding management. 45 PCPs are encouraged to optimize the nutritional status of transplant candidates with appropriate corticosteroid withdrawal and avoidance, nutritional counseling, dietary modification, and exercise and lifestyle changes by following guidelines where available. 50, 51 In select lung transplant cases, bariatric surgery may be helpful for weight loss and reduction of comorbidities.
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Optimizing Adherence
The treatment regimen of a patient who has received a transplant consists of lifelong medication therapy; regular evaluation for therapeutic drug monitoring (TDM); surveillance for rejection, infection, or other complications; mitigating risk factors for cardiovascular 
Restricted Transfusion of Blood Products
As in the general population, patients may develop acute lung injury from transfusion of blood products. 60 Repeated transfusion of blood products 61 increases the risk of developing donor-specific anti-human leukocyte antigen antibodies in the sera of transplant recipients (humoral sensitization), raising the potential for acute rejection and mortality. 61, 62 To prevent transfusionassociated graft-vs-host disease in patients who are immunocompromised who are treated with lymphocyte-depleting monoclonal antibodies, a rare condition, irradiation of whole blood and blood components is currently recommended. 63, 64 In the posttransplant phase, patients who are cytomegalovirus (CMV) seronegative who are receiving seronegative organs should receive CMV-safe blood products (leukoreduced or from donors who are CMV seronegative). Overall, the benefit of transfusion of any blood product needs to outweigh the risk, and alternatives to the use of blood products should be encouraged.
Immunization
Every effort should be made to ensure the transplant candidates, close contacts, and health-care workers have completed the recommended vaccinations prior to transplant. 65 The vaccination status of potential transplant candidates is reviewed at the first clinic visit and a strategy decided on. [65] [66] [67] Any patient receiving high-dose corticosteroids or immunosuppressive medications should avoid live attenuated vaccines, including influenza virus (inactivated influenza vaccine is safe), rotavirus, varicella zoster, measles, mumps, and rubella. 65 The US Centers for Disease Control and
Prevention website provides direct access to vaccination recommendations at http://www.cdc.gov/vaccines.
Cotreatment of Patients After Transplant
The important factors to consider in care after lung transplant include the altered immune system, the denervated lung graft, and a high potential for drugdrug interactions.
Routine Posttransplant Care
Hypertension: The 5-year prevalence of hypertension in adults after lung transplant approaches 62%, 68, 69 surpassing that of the general US population. 70 The 2014 80 In suboptimal glycemic control, a more aggressive approach such as the use of an insulin pump may be beneficial. 80 Dietary and lifestyle modifications such as exercise and weight optimization and annual screening are performed as in the general population.
Dyslipidemia: Hyperlipidemia is prevalent and predicts rapid decline in renal function, greater incidence of major cardiovascular events, and worsened mortality in lung transplant recipients. 81, 82 Drug therapy is initiated in patients with a history of heart disease, stroke, and low-density lipoprotein cholesterol levels > 190 mg/dL; patients with DM aged 40 to 75 years with a low-density lipoprotein cholesterol level of 70 to 189 mg/dL; and patients with a global 10-year risk of cardiovascular disease that exceeds 7.5%. Current guidelines in patients with transplants suggest statins as first-line therapy for hypercholesterolemia. 83 However, caution and clinical judgment must be used when a combination of statins and/or fibrates with CNIs is used due to the increased risk of rhabdomyolysis and nephrotoxicity. 84, 85 Bone Health: In lung transplant candidates, the prevalence of osteoporosis and combined osteopenia and osteoporosis exceed 37% and 69%, respectively. 86, 87 Hence, vitamin D levels and bone mineral density are routinely included in the evaluation of lung transplant candidates. Avoidance of tobacco and alcohol and regular weight-bearing exercise help preserve bone density. After lung transplant, all patients should receive the recommended daily allowance for calcium (1,000-1,500 mg/d) and vitamin D (400-800 IU/d). Studies in lung transplant recipients suggest that bisphosphonate may be the most effective choice in the prevention of increased bone resorption and rapid bone loss early after transplant, 88, 89 and recombinant human parathyroid hormone (teriparatide) remains useful in the treatment of glucocorticoid-induced osteoporosis. 90, 91 After initial bone mineral density assessment, follow-up testing can range from 2 to 3 years for those with osteopenia and normal bone mineral density and annually for those with osteoporosis.
Psychologic Issues, Return to Work, Recreation, and Life: Transplant recipients become increasingly selfreliant and independent as they progress further into the years after lung transplant; however, when persistent, depressive symptoms and lower neurocognitive performance are associated with decreased survival. 92, 93 Selective serotonin reuptake inhibitors are well tolerated and effective therapies for depression, posttraumatic stress disorder and panic disorder. Among these medications, the risk of drug-drug interactions appears to be least in patients receiving citalopram and escitalopram. 94 In difficult cases, referral for therapeutic intervention by psychiatrists with a special interest in LTx may be required.
Soon after transplant, patients often look and feel like they had before transplant, and many wish to resume their pretransplant healthy lifestyle. 95 Posttransplant employment rates vary substantially and could exceed 40%. 95 The only restrictions would be to avoid activities that could potentially increase the risk of infections. To our knowledge, there are no studies specifically addressing limitations in return to driving and operating a vehicle in patients with lung transplants.
Reproductive Health: Pregnant lung transplant recipients are at increased risk of acute rejection and progressive graft dysfunction, so spirometry should be monitored and changes investigated. Approximately 40% to 50% of pregnancies among lung transplant recipients result in a live birth. 96, 97 The incidence of birth defects appears similar to that in the general population but is increased for pregnancies in patients using mycophenolate and mechanistic target of rapamycin (mTOR) inhibitors. 97 Although pregnancy is not discouraged in patients with lung transplants, the process is best meticulously planned. 98 Genetic counseling is crucial for patients with hereditary diseases, including heritable pulmonary hypertension, CF, familial pulmonary fibrosis, and alpha-1 antitrypsin deficiency. Although the timing is an area of debate, most centers recommend waiting for 1 to 2 years after lung transplant before conception. 96, 99 Patients need to be counseled regarding the relatively limited long-term survival of lung transplant recipients and the impact of pregnancy on long-term outcomes further confounding the ability to participate in raising the child. Extrapolation from heart transplant data suggests that paternity by lung transplant recipients may be safe.
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Cancer Screening and Preparation for Surgical Procedures: Malignancy is a major cause of late deaths in lung transplant survivors, with prevalence increasing across time to 20% 10 years after lung transplant. 101 Lung cancer risk is increased sixfold in lung transplant recipients. 102 In addition to the usual risk factors effective in the general population, such as exposure to tobacco, alcohol use, age, and genetic predisposition, immunosuppression-induced reduction of cancer immunosurveillance and a higher risk of oncogenic viral infections increase the incidence of malignancy. 103, 104 Dermatologic malignancies, especially squamous cell and basal cell carcinoma, are the most frequent malignancies in organ transplant recipients 105 ; therefore, skin cancer surveillance with dermatologic examinations every 6 or 12 months is recommended.
106,107 mTOR inhibitors, sirolimus, and everolimus have antineoplastic properties and are associated with significantly reduced risk of developing posttransplant malignancy. 108 Lung transplant recipients also have an increased incidence of the relatively rare tumors, such as posttransplant lymphoproliferative disorders, Kaposi sarcoma, and various sarcomas. 109 The beneficial effect of aggressive management and treatment for earlier-stage disease underscores the need for regular screening (Table 1) .
Lung transplant recipients can safely undergo surgery when their clinical care is optimized. Sirolimus and everolimus may impair wound healing, so the risks and benefits of preoperative cessation and replacement with another agent should be discussed. Lung transplant recipients receiving corticosteroid therapy may require perioperative stress-dose steroids.
Drug Interactions
The primary immunosuppressive therapies commonly used in various combinations for maintenance in patients with lung transplants include corticosteroids, CNIs, antimetabolite cell cycle blockers, and mTOR inhibitors. 110 CNIs and mTOR inhibitors are metabolized through the cytochrome P450 3A4 system and have significant interactions with many commonly used medications (Table 4) . 111 Modest alterations in medication doses may lead to therapeutic failure or severe adverse drug reactions because of their narrow therapeutic indexes. Such consequences may be irreversible and could result in graft loss, disability, or death. TDM is routinely performed for mTOR inhibitors and CNIs to minimize these risks.
Although TDM is not commonly used for mycophenolate or azathioprine, a number of drug interactions are particularly important: Bile acid sequestrants, antacids, proton pump inhibitors, and rifampin decrease serum concentrations of mycophenolate, whereas acyclovir and valacyclovir increase the levels. Severe bone marrow suppression and cytopenias may occur when azathioprine is used concurrently with allopurinol, captopril, or other angiotensin-converting enzyme inhibitors. 112, 113 The transplant center should thus be informed about all medication changes to enable closer monitoring of therapeutic levels until a steady-state level is achieved. Changes in immunosuppressant medications should be made only by the transplant center.
Caution With Generic Substitution of Immunosuppressant Medications: Exposing the lung transplant recipient to different generic formulations of a particular immunosuppressant medication could result in adverse outcomes because of the potential variation in their pharmacokinetic effects and drug-drug interactions.
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The International Society for Heart and Lung Transplantation recommends that 114 (1) patients inform their care coordinators of any potential generic drug substitution of their immunosuppressant medications, (2) generic immunosuppressants should be used with a high degree of caution, and (3) surveillance strategies and frequent TDM should be implemented until stable immunosuppression is achieved.
Common Complications and Emergencies
Allograft Rejection: Despite advances in immunosuppression, the life expectancy of lung transplant recipients remains limited by the occurrence of organ rejection. During the first weeks after transplant, rejection can be classified as (1) acute cellular rejection (ACR), which is T-cell mediated; (2) acute humoral rejection (HR), which is B-cell mediated; and (3) chronic rejection.
ACR is prevalent in the first year after transplant and may affect 50% to 90% of patients. Because patients may be asymptomatic, surveillance, which includes the use of spirometry, is commonly used. FEV 1 and vital capacity may be decreased in $ 60% of rejection episodes. 116 Any decline that exceeds 10% in home spirometric monitoring should be confirmed with formal spirometry. ACR may manifest with nonspecific symptoms, including hypoxemia, fever, malaise, dyspnea, cough, and fatigue, with or without radiographic airspace opacities. 117 Clinical and radiographic evaluation, pulmonary function tests, bronchoscopic examination, lavage, and transbronchial biopsies are important in the differential diagnosis. At histologic evaluation, the severity of ACR is graded on a scale of 0 (absent) to 4 (severe). 118 Treatment with high-dose steroids or T-cell-depleting antibodies is often necessary because recurrent or severe episodes of acute rejection increase the risk for allograft dysfunction.
HR is increasingly recognized in LTx. Although the exact underlying mechanisms are poorly understood, HR is thought to result from complement activation and graft dysfunction due to preexisting or de novo donor-specific antibodies, present in up to 15% of lung transplant recipients. [119] [120] [121] The clinical manifestation of acute HR is similar to that of ACR, and pathologic demonstration of vascular endothelial inflammation and immunologic evidence of complement deposition should heighten suspicion for acute HR. 118 B-cell depleting therapies such as intravenous immunoglobulin and rituximab with or without plasmapheresis have demonstrated usefulness in clearing donor-specific antibodies.
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After the first year, the risk of acute rejection substantially decreases but is never eliminated. When declining lung function persists for at least 3 weeks without the FEV 1 and/or FVC returning to > 90% of the postoperative best values, chronic lung allograft dysfunction is suspected. This dysfunction commonly manifests as a physiologic obstruction and is caused by obliterative bronchiolitis, which is characterized by a fibroproliferative airway response from alloimmune and nonalloimmune factors (bronchiolitis obliterans syndrome). 125, 126 Less commonly, chronic lung allograft dysfunction may manifest as a restrictive pattern (FVC < 80% of posttransplant baseline FVC) with predominantly upper zone subpleural infiltrates (restrictive allograft syndrome). 127, 128 Chronic rejection in either the restrictive or obstructive form remains the leading cause of death during the first year after lung transplant and affects up to one-half of all those surviving beyond 5 years.
Infectious Complications: Lung transplant recipients are at constant risk of infection, which remains one of the most important causes of postoperative morbidity and mortality. Multiple factors contribute to the dramatic reduction in airway defense mechanisms. These include surgical denervation, loss of mucosal barrier, lack of bronchial artery vascularization, disrupted lymphatic channels, blunted cough reflex, and impaired mucociliary clearance. Additionally, immunosuppressive therapy and continuous environmental exposure to irritants and microorganisms heighten this risk. Infections can be acquired endogenously, from donors, or from the environment. Lung transplant recipients are thus counseled on strategies for safe living and ways to minimize the risk of infection (Table 5) . 129 Early and specific diagnosis must be accompanied by rapid and aggressive clinical treatment to optimize infection outcomes in patients with transplants. In the first 6 months after lung transplant, viruses such as CMV, Epstein-Barr virus, human herpesvirus 6 cause clinical disease; and in combination with higher immunosuppressant levels can lead to opportunistic infections such as Listeria monocytogenes, Aspergillus fumigatus, and Pneumocystis jirovecii even without an intense exposure. Despite universal prophylaxis, CMV infection will occur in up to one-third of lung transplant recipients within the first postoperative year. Prophylaxis with oral valganciclovir decreases risk of CMV infection and disease severity. 130, 131 Quantification of circulating or alveolar lavage CMV viral load by using nucleic acid amplification testing techniques or pp65 assays does not always correlate with tissue invasion, and definitive diagnosis requires demonstration of characteristic inclusion bodies or antigens in the lung tissue or alveolar lavage cells. 131 Patients with symptomatic infection (CMV syndrome) frequently present with malaise, fever, leukopenia, nonproductive cough, and hypoxemia. CMV infection may also involve other organ systems such as tissueinvasive disease in the central nervous system, liver, and gastrointestinal tract. A 2-to 3-week course of induction with ganciclovir or valganciclovir, followed by maintenance with valganciclovir, is typically used for therapy. 131 Ganciclovir resistance should be suspected with clinical treatment failure or breakthrough viremia. 131 Alternate therapies such as cidofovir or foscarnet should be explored after confirmation of mutations that confer resistance to ganciclovir.
Bacteria such as Pseudomonas aeruginosa and Staphylococcus aureus are among the fatal causes of infection in the early period after lung transplant. 132 Pneumocystis pneumonia, which is up to five times more prevalent after lung than other organ transplants, may be diminished with the routine use of prophylactic agents such as trimethoprim-sulfamethoxazole. 133 Fungal infections are more common in recipients of lung transplants than of most other solid organs 134, 135 and are predominantly due to candida (extrapulmonary infection) or Aspergillus, 134, 135 and less commonly
Cryptococcus neoformans and the endemic fungi. Although extrapulmonary candida infections have been declining, Aspergillus remains a predominant cause of pulmonary fungal infection in lung transplant recipients. Although consensus on the choice of antifungal agents, route of administration, and duration of prophylaxis has not been established, oral azoles and inhaled amphotericin are useful agents in the prophylaxis of airway aspergillosis. 136 Conversely, invasive pulmonary aspergillosis characterized by isolated or multiple radiographic nodules with or without cavitation (halo sign) is more severe and frequently occurs within 1 year after lung transplant. 137 Serum and bronchoalveolar lavage galactomannan have a high specificity for the organism, but poor sensitivity for diagnosis, 138 and the role of nucleic acid amplification testing is evolving. Therefore, tissue sampling is often required for definitive 141 Nontransplant physicians are encouraged to contact the transplant center at the earliest suspicion of infection because of the broad spectrum of potential pathogens and the nonspecificity of signs and symptoms in patients with lung transplants (Table 6 ).
Conclusions
An increasing population is experiencing the benefits of LTx as an effective treatment for advanced chronic respiratory failure. However, a larger proportion of patients remain in need of lung transplant. Effective collaboration between transplant and nontransplant physicians is required to meet this demand and sustain progressive improvement in survival and quality-of-life outcomes. We have outlined the salient parts of this partnership and hope this stimulates further discussion among all parties involved to ensure that the care of this vulnerable transplant population is seamlessly integrated.
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